

Date: December 19, 2024

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Qualified Institutions Placement of Equity Shares of face value of ₹1 each (the “Equity Shares”) by Mankind Pharma Limited (the “Company”) under the provisions of Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”), and Sections 42 of the Companies Act, 2013 (including the rules made thereunder), as amended (the “Issue”)

Further to our earlier communication dated December 16, 2024 on the captioned subject, we wish to inform you that the Fund Raising Committee of Directors of the Company at its meeting held today i.e. December 19, 2024, has inter- alia, considered and approved the following:

1. Approved and declared the closure of the issue period for the Issue today (i.e. December 19, 2024), pursuant to the receipt of application forms and the funds in the escrow account from the eligible qualified institutional buyers in accordance with the terms of the Issue;
2. Determined and approved the allocation of 1,19,04,761 Equity Shares at an Issue price of ₹2,520/- per Equity Share (including a premium of ₹2,519 per Equity Share) which is at a discount of 3.69% (i.e. ₹96.55 per Equity Share) to the floor price of ₹ 2616.55/- per Equity Share determined according to the formula prescribed under Regulation 176(1) of Chapter VI of the SEBI ICDR Regulations for the Equity Shares to be allotted to the eligible qualified institutional buyers in the Issue;
3. Approved and adopted the placement document dated December 19, 2024 in connection with the Issue. Copy of the same is being also made available on the website of the Company at <https://www.mankindpharma.com/investors-relations/>
4. Approved and finalised the confirmation of allocation note to be sent to eligible qualified institutional buyers, intimating them of the allocation of Equity Shares pursuant to the Issue.

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com



The meeting of the Fund Raising Committee of Directors of the Company commenced at 10:00 pm IST and concluded at 10:20 pm IST.

The Issue was opened on December 16, 2024 and the same was intimated to you pursuant to our letter dated 16 December, 2024.

We request you to take the above on record and treat the same as compliance under the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

The information in the above intimation is also being uploaded on the website of the Company at www.mankindpharma.com.

You are requested to kindly take the same on record.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Ashish Mittal
Company Secretary and Compliance Officer